ClinicalTrials.gg
CompletedNCT04796623Updated Apr 8, 2026

A Study of TQB3616 Capsules Combined With Fulvestrant Injection in Subjects With Advanced Breast Cancer

A Phase 2 interventional study of TQB3616 capsules and Fulvestrant injection in HR-positive, HER2-negative Advanced Breast Cancer, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Completed at 17 sites in China. Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-04-08.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
122
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies testing culmerciclib in Breast Neoplasms — 8 open to participants now, 11 under way, 2 of them phase 3. culmerciclib · Breast Neoplasms.

Enrollment
4th of 15
122 · median 40
Started
2021
with 1 other
Phase 2
9 of 15
7 open now
Registered
2nd of 15
by date
Lead sponsor
8 of 15
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Among the 15 studies testing culmerciclib in Breast Neoplasms, this one is the 4th largest by enrollment, is one of 2 that started in 2021, is one of 9 in phase 2, and was the 2nd registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

8 of the 15 studies testing culmerciclib in Breast Neoplasms are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

About culmerciclib

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years to 75 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing culmerciclib in Breast Neoplasms, or all of them as a file.
02

Study summary

This study is a multicenter, open-label, multi-cohort phase II clinical trials to evaluate the efficacy and safety of TQB3616 capsules combined with Fulvestrant injection in subjects with HR-positive and HER2-negative advanced and/or metastatic breast cancer, including Cohort 1 and Cohort 2. Each cohort will enroll 30-60 cases.

03

Conditions studied

  • HR-positive, HER2-negative Advanced Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1.Understood and signed an form. 2. (ECOG) performance status of 0 to 1; ≥ 3 months. 3. Histopathologically confirmed HR positive and negative advanced or breast cancer. 4.Cohort 1: patients had received ≤1 . 5.Cohort 2: patients had not previously received systemic antitumor therapy. 6.Has at least one according to RECIST1.1 criteria. 7.Adequate laboratory indicators.

Exclusion criteria

Exclusion Criteria:

  • 1. Concomitant disease and medical history:

    1. Has other malignant tumors within 3 years;
    2. Has multiple factors affecting oral medication;
    3. Unalleviated toxicity ≥ grade 1 due to any previous anticancer therapy;
    4. Has active or uncontrolled severe infections before the first dose;
    5. Cirrhosis, active hepatitis#
    6. Have a history of immunodeficiency; 2. Tumor-related symptoms and treatment:

    <!-- -->

    1. Has central nervous system (CNS) and/or cancerous meningitis or ;
    2. Had received chemotherapy within 3 weeks prior to the first dose, and had received radiotherapy , hormone therapy, or other anti-tumor therapy within 2 weeks prior to the first dose;
    3. Has uncontrollable pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures.

      3. Has known to be allergic to Fulvestrant injection , TQB3616 or any .

      4. Has Participated in other clinical trials within 4 weeks before first dose. 5. According to the judgement of the investigators, there are other factors that may lead to the termination of the study.

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
122 participants (actual)

Study arms

  • Experimental
    TQB3616 capsules combined with fulvestrant injection

    TQB3616 capsules 180 mg given orally, once daily in 28-day cycle. Fulvestrant injection was given at a fixed dose of 500mg on day 1, day 15 of the first cycle and day 1 of each subsequent cycle, and each cycle is 28 days.

    Drug: TQB3616 capsules · Drug: Fulvestrant injection

Interventions

  • TQB3616 capsules 180 mg given orally, once daily in 28-day cycle.

  • Fulvestrant injection was given at a fixed dose of 500mg on day 1, day 15 of the first cycle and day 1 of each subsequent cycle, and each cycle is 28 days.

06

What researchers measure

Primary outcomes

  1. Overall response rate (ORR) assessed by investigator

    ORR defined as percentage of participants achieving complete response (CR) and partial response (PR), recorded from the first dose until the first documented progressive disease (PD) or death from any cause, based on investigator.

    Time frame: Baseline up to 24 months

Secondary outcomes

  1. Progression free survival (PFS)

    PFS defined as the time from first dose until the first documented progressive disease (PD) or death from any cause.

    Time frame: Baseline up to 24 months

  2. Overall survival (OS)

    OS defined as the time from first dose to death from any cause. Participants who do not die at the end of the extended follow-up period, or were lost to follow-up during the study, were censored at the last date they were known to be alive.

    Time frame: Baseline up to 24 months]

  3. Clinical benefit rate (CBR)

    Percentage of participants achieving complete response (CR) and partial response (PR) and stable disease (SD).

    Time frame: Baseline up to 24 months

  4. Duration of Response (DOR)

    The time when the participants first achieved complete or partial remission to disease progression.

    Time frame: Baseline up to 24 months

07

Study locations

17 sites
  • The Fifth Medical Center of PLA General Hospital
    Beijing, Beijing Municipality 100039, China
  • Chongqing University Cancer Hospital
    Chongqing, Chongqing Municipality 400000, China
  • Gansu Provincial Hostipal
    Lanzhou, Gansu 730030, China
  • Guangdong General Hospital
    Guangzhou, Guangdong 510062, China
  • Sun Yat-sen University Cancer Center
    Guangzhou, Guangdong 510062, China
  • Guangxi Medical University Affiliated Tumor Hospital
    Nanning, Guangxi 530021, China
  • The Fourth Hospital of Hebei Medical University
    Shijiazhuang, Hebei 050011, China
  • Harbin Medical University Affiliated Cancer Hospital
    Harbin, Heilongjiang 150000, China
  • Hunan Cancer Hospital
    Changsha, Hunan 410013, China
  • Jiangsu Province Hospital
    Nanjing, Jiangsu 210029, China
  • The Second Hospital of Dalian Medical University
    Dalian, Liaoning 116027, China
  • Liaoning Cancer Hospital & Institute
    Shenyang, Liaoning 110042, China
  • Shanghai East Hospital
    Shanghai, Shanghai Municipality 200123, China
  • The Second Affiliated Hospital of PLA Air Force Military Medical University
    Xi’an, Shanxi 710038, China
  • The First Affiliated Hospital of Xi'an Jiao Tong University
    Xi’an, Shanxi 710061, China
  • Affiliated Tumor Hospital of Xinjiang Medical University
    Ürümqi, Xinjiang 830000, China
  • The First Affiliated Hospital Zhejiang University School of Medicine
    Hangzhou, Zhejiang 310003, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2021 to primary completion in May 2024, 39 months.

Of 232 industry-sponsored phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 53. This study's 39 months is above that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 11, 2021
First posted
Mar 15, 2021
StartActual
Feb 4, 2021
Primary completionActual
May 24, 2024
CompletionActual
May 24, 2024
Last update
Apr 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04796623
Responsible party
Sponsor
First posted
Mar 15, 2021
Start date
Feb 4, 2021
Primary completion
May 24, 2024
Completion
May 24, 2024
Last update
Apr 8, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Culmerciclib

Start the discussion